EP0640609A1 — Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
Assigned to Ono Pharmaceutical Co Ltd · Expires 1995-03-01 · 31y expired
What this patent protects
Fused phenol derivatives of the formula (I): (wherein R¹ and R² each, independently, is H, halogen, trifluoromethyl, cyano, (substituted) alkyl, alkoxy, cycloalkyl, COOH, COOR⁶ (in which R⁶ is C1-6 alkyl), alkenyl or R¹ and R², taken together, is -CH=CH-CH=CH-, when R¹ a…
USPTO Abstract
Fused phenol derivatives of the formula (I): (wherein R¹ and R² each, independently, is H, halogen, trifluoromethyl, cyano, (substituted) alkyl, alkoxy, cycloalkyl, COOH, COOR⁶ (in which R⁶ is C1-6 alkyl), alkenyl or R¹ and R², taken together, is -CH=CH-CH=CH-, when R¹ and R² are attached ortho to each other; A is alkylene, alkenylene, oxyalkylene or (in which m is 1-6); B is monocyclic hetero ring containing nitrogen atom; G is -OR 3A or -NR 3B R 3C (in which R 3A , R 3B and R 3C each, independently, is H, alkyl, acyl, or alkoxyalkyl); R⁴ and R⁵ each, independently, is H, alkyl, or R⁴ and R⁵ together with the carbon atom to which they are attached is C4-7 cycloalkyl; n is 1-3; and non-toxic salts thereof, non-toxic acid addition salts thereof and hydrates thereof, have utility as pharmaceuticals.
Drugs covered by this patent
- Oxbryta (voxelotor) · Global Blood Theraps
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.